NEW BRUNSWICK, N.J. — Rutgers researchers have discovered how HIV-1, the virus that causes AIDS, resists AZT, a drug widely used to treat AIDS.
The scientists, who report their findings in Nature Structural & Molecular Biology, believe their discovery helps researchers understand how important anti-AIDS treatments can fail and could help AIDS researchers develop more effective treatment for the disease.
“What we’ve found is the detailed way in which the mutations act to promote the resistance,” said author Eddy Arnold, Board of Governors Professor of Chemistry and Chemical Biology, and a resident faculty member of the Center for Advanced Biotechnology and Medicine. “Instead of blocking the actions of AZT, the virus actually removes it, and it does so by using ATP, one of the most common cellular molecules. This is an outstanding example of how sneaky HIV can be in thwarting the efficacy of therapeutic drugs.”
AZT was once the only treatment for AIDS, and it remains an important treatment, particularly in preventing the transmission of the virus from infected mothers to their unborn children.
Researchers knew almost from the beginning that the virus developed resistance to AZT, and that this resistance had to do with mutations, but the way the mutations worked to resist the drug was mysterious.
AZT works by inhibiting an enzyme, reverse transcriptase, which HIV needs to produce DNA from RNA, and thus replicate itself. About 10 years ago, biochemical studies in several laboratories established that AZT-resistant HIV-1 reverse transcriptase uses adenosine triphosphate, or ATP, which moves energy around inside the cell, to remove the AZT. Arnold and his co-authors have used X-ray crystallography to describe in atomic detail how the AZT-resistance mutations allow reverse transcriptase to recruit ATP to remove the AZT.
Arnold’s co-authors are Roger Jones, professor of chemistry and chemical biology at Rutgers; Xiongying Tu, Kalyan Das, Qianwei Han, Arthur D. Clark Jr., Yulia Frenkel and Stefan G. Serafianos, of the Center for Advanced Biotechnology and Medicine; and Stephen Hughes and Paul Boyer of the National Cancer Institute in Frederick, Md. The Center for Advanced Biotechnology and Medicine is a joint center of Rutgers University and the University of Medicine and Dentistry of New Jersey. The study was funded by the National Institutes of Health, by grants from both the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute of General Medical Sciences (NIGMS), both part of the National Institutes of Health. Arnold has received two consecutive MERIT (Merit to Extend Research in Time) Awards from NIAID, an honor bestowed on less than five percent of NIH grant recipients.